Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q3 2021 · 10-Q
Revenue$13.29M$13.29M+60.9% vs Q3 2020 Net Income-$14.56M-$14.56MN/M vs Q3 2020 EPS Diluted-$0.37-$0.37N/M vs Q3 2020 Operating Income-$7,968,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$9,148,000N/M Margins · derivedOperating margin-60.0%+106.9 pt vs Q3 2020
Net margin-109.5%+90.8 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 2, 2021 · 33 d after period end